AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19117801 — intervention group
Group type: COMPARATOR
Intervention: Physician directed product administration
Number of subjects: 69
Study 17102916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed ePTFE graft (Venaflo)
Number of subjects: 36
Study 17102916 — intervention group
Group type: COMPARATOR
Intervention: Non-cuffed standard ePTFE graft (Gore-Tex)
Number of subjects: 36
Study 15497388 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Pump (Medtronic)
Number of subjects: 20
Study 15497388 — intervention group
Group type: EXPERIMENTAL
Intervention: Revolution (Cobe)
Number of subjects: 20
Study 15497388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 11302353 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about a positive future
Number of subjects: 40
Study 11302353 — intervention group
Group type: COMPARATOR
Intervention: No-writing control group
Number of subjects: 40
Study 9145738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ofloxacin followed by oral ofloxacin for 14-28 days
Number of subjects: 108
Study 9145738 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ampicillin/sulbactam followed by oral amoxicillin/clavulanate for 14-28 days
Number of subjects: 108
Study 7893571 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (body resistance: R)
Number of subjects: 102
Study 7893571 — intervention group
Group type: EXPERIMENTAL
Intervention: Plicometry (triceps, biceps, subscapular, and suprailiac skinfolds)
Number of subjects: 102
Study 7893571 — intervention group
Group type: EXPERIMENTAL
Intervention: Plicometrically‐determined FM% and FFM‐Kg
Number of subjects: 102
Study 7893571 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction formulas for plicometric FM and FFM from body resistance and anthropometric variables
Number of subjects: 102
Study 3250315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 76
Study 3250315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 76
Study 3250315 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 76
Study 3250315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil
Number of subjects: 76
Study 3250315 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 76
Study 31923472 — intervention group
Group type: EXPERIMENTAL
Intervention: CareAvenue - an automated e-health tool that screens for unmet social risk factors and informs and activates individuals to connect to resources and engage in self-care (15-20 min web-based program with routine follow-up).
Number of subjects: 720
Study 31923472 — intervention group
Group type: COMPARATOR
Intervention: Standard care - receipt of contact information for existing health system assistance services.
Number of subjects: 720
Study 30287671 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride + Linagliptin
Number of subjects: 0
Study 30287671 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride + Placebo
Number of subjects: 0
Study 26883283 — intervention group
Group type: EXPERIMENTAL
Intervention: DISCOVER intervention (open-access psychological workshops using CBT methods, delivered in a 1-day workshop with additional telephone support)
Number of subjects: 0
Study 26883283 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 0
Study 25153961 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-factor model of the Foreign Language Classroom Anxiety Scale (FLCAS)
Number of subjects: 461
Study 22166471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg
Number of subjects: 24
Study 22166471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 24
Study 22166471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg
Number of subjects: 24
Study 22166471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20683455 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron and vitamin B(12) fortification (100% RDA)
Number of subjects: 543
Study 20683455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low iron and vitamin B(12) fortification (15% RDA)
Number of subjects: 543
Study 20683455 — intervention group
Group type: COMPARATOR
Intervention: Control group (without H. pylori infection)
Number of subjects: 543
Study 18461016 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1 g once daily for 24 weeks
Number of subjects: 384
Study 18461016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 15938885 — intervention group
Group type: EXPERIMENTAL
Intervention: TMJ pain treatment
Number of subjects: 51
Study 15938885 — intervention group
Group type: COMPARATOR
Intervention: Control (no TMJ treatment)
Number of subjects: 51
Study 11436967 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous cluster VIT
Number of subjects: 55
Study 11436967 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous rush VIT
Number of subjects: 55
Study 11436967 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot cluster VIT
Number of subjects: 55
Study 9564194 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability training sessions for the 17-item Hamilton Depression Rating Scale
Number of subjects: 0
Study 7996803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis fluid with 10 mmol/liter glucose (GD)
Number of subjects: 8
Study 7996803 — intervention group
Group type: COMPARATOR
Intervention: Dialysis fluid without glucose (GFD)
Number of subjects: 8
Study 7996803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis fluid with glucose (GD)
Number of subjects: 8
Study 3046553 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (up to 900 mg/d)
Number of subjects: 268
Study 3046553 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (up to 1800 mg/d)
Number of subjects: 268
Study 3046553 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 268
Study 3046553 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 268
Study 31396815 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study 31396815 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic pill bottles for medication adherence monitoring
Number of subjects: 149
Study 31396815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional text messaging for medication adherence monitoring
Number of subjects: 149
Study 27738832 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin emulgel (2%)
Number of subjects: 66
Study 27738832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 23435032 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% 17β‐estradiol gel (n = 15)
Number of subjects: 30
Study 23435032 — intervention group
Group type: COMPARATOR
Intervention: 4% genistein gel (n = 15)
Number of subjects: 30
Study 21912122 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐type natriuretic peptide‐32 (BNP‐32)
Number of subjects: 112
Study 21912122 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐reactive protein (CRP)
Number of subjects: 112
Study 21912122 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin‐1 (ET‐1)
Number of subjects: 112
Study 21912122 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin‐6 (IL‐6)
Number of subjects: 112
Study 21912122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (TPA)
Number of subjects: 112
Study 19052054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide 500 microg (IB)
Number of subjects: 16
Study 19052054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17073895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 45
Study 14980929 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg orally (DiazG)
Number of subjects: 45
Study 14980929 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg intrathecally (Clon(i/t)G)
Number of subjects: 45
Study 14980929 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg orally (Clon(p/o)G)
Number of subjects: 45
Study 11260571 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy (AT)
Number of subjects: 32
Study 9773865 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ganciclovir
Number of subjects: 72
Study 9773865 — intervention group
Group type: COMPARATOR
Intervention: 3-times-weekly ganciclovir
Number of subjects: 72
Study 8148356 — intervention group
Group type: COMPARATOR
Intervention: 0 eggs per day
Number of subjects: 20
Study 8148356 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 egg per day
Number of subjects: 20
Study 8148356 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 eggs per day
Number of subjects: 20
Study 8148356 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 eggs per day
Number of subjects: 20
Study 2607293 — intervention group
Group type: EXPERIMENTAL
Intervention: High-temperature thermoplasticized gutta-percha
Number of subjects: 45
Study 2607293 — intervention group
Group type: EXPERIMENTAL
Intervention: High copper amalgam
Number of subjects: 45
Study 2607293 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm gutta-percha
Number of subjects: 45
Study 2607293 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no leakage)
Number of subjects: 45
Study 2607293 — intervention group
Group type: COMPARATOR
Intervention: Positive control (complete leakage)
Number of subjects: 45
Study 31353158 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 24
Study 31353158 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 24
Study 30655509 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic drug amisulpride
Number of subjects: 325
Study 30655509 — intervention group
Group type: EXPERIMENTAL
Intervention: C1A subtype
Number of subjects: 325
Study 30655509 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model
Number of subjects: 325
Study 26948303 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol for early detection of symptoms and advanced care planning structured protocol for acute decompensations
Number of subjects: 0
Study 26948303 — intervention group
Group type: COMPARATOR
Intervention: Parallel and historical cohort for comparison
Number of subjects: 0
Study 25130768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot moisturizing formulation
Number of subjects: 18
Study 25130768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold moisturizing formulation
Number of subjects: 18
Study 25130768 — intervention group
Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 18
Study 22476964 — intervention group
Group type: COMPARATOR
Intervention: Northern European patients starting hemodialysis with a catheter for vascular access (23%)
Number of subjects: 647
Study 22476964 — intervention group
Group type: COMPARATOR
Intervention: Southern European patients
Number of subjects: 647
Study 22476964 — intervention group
Group type: COMPARATOR
Intervention: Northern European patients (adjusted for age, sex, membrane permeability, comorbidity index, vascular access)
Number of subjects: 647
Study 21851166 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol-brimonidine fixed combination (BTFC)
Number of subjects: 60
Study 21851166 — intervention group
Group type: COMPARATOR
Intervention: Timolol-dorzolamide fixed combination (DTFC)
Number of subjects: 60
Study 19692842 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 postcontrast (T1(Gd))
Number of subjects: 30
Study 19692842 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaR1
Number of subjects: 30
Study 19692842 — intervention group
Group type: COMPARATOR
Intervention: Reference cartilage T1 postcontrast
Number of subjects: 30
Study 19692842 — intervention group
Group type: COMPARATOR
Intervention: Reference cartilage DeltaR1
Number of subjects: 30
Study 19692842 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between T1(Gd) and DeltaR1 for repair tissue
Number of subjects: 30
Study 19692842 — intervention group
Group type: COMPARATOR
Intervention: Correlation between T1(Gd) and DeltaR1 for normal reference cartilage
Number of subjects: 30
Study 19692842 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative interval
Number of subjects: 30
Study 19692842 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle postoperative interval
Number of subjects: 30
Study 19692842 — intervention group
Group type: EXPERIMENTAL
Intervention: Late postoperative interval
Number of subjects: 30
Study 19692842 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cartilage repair tissue and reference cartilage
Number of subjects: 30
Study 19692842 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of early follow-up and later postoperative groups for cartilage repair tissue
Number of subjects: 30
Study 19692842 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between the 2 later follow-up groups of reparative cartilage
Number of subjects: 30
Study 16200592 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at 3.0T with 1.0-mm partition thickness
Number of subjects: 30
Study 16200592 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at 3.0T with 1.5-mm partition thickness
Number of subjects: 30
Study 16200592 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at 1.5T with 1.5-mm partition thickness
Number of subjects: 30
Study 16200592 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at 3.0T
Number of subjects: 30
Study 14668608 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position for 10 days for 6 hrs/day
Number of subjects: 225
Study 10529659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately early dexamethasone group (14 days, total dose 4.75 mg/kg)
Number of subjects: 30
Study 10529659 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dexamethasone group (7 days, total dose 2.38 mg/kg)
Number of subjects: 30
Study 10529659 — intervention group
Group type: COMPARATOR
Intervention: Control group (for both phases)
Number of subjects: 30
Study 7571981 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori gastritis
Number of subjects: 36
Study 7571981 — intervention group
Group type: COMPARATOR
Intervention: No Helicobacter pylori infection
Number of subjects: 36
Study 2694418 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5, 10, and 15 mg/l)
Number of subjects: 8
Study 2694418 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline (1.25, 2.5, and 3.75 mg/l)
Number of subjects: 8
Study 2694418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 866904 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin
Number of subjects: 18
Study 866904 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin with 10 mg diazepam
Number of subjects: 18
Study 866904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31759611 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer measurements at 1 Hz (in 1-s intervals) at the vertical axis
Number of subjects: 48
Study 31759611 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant analysis
Number of subjects: 48
Study 31759611 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleration peaks
Number of subjects: 48
Study 30345860 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress
Number of subjects: 21
Study 30345860 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stress
Number of subjects: 21
Study 30345860 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 28655793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years
Number of subjects: 57
Study 28655793 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 57
Study 28655793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 57
Study 25268656 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin + standardized self-rehabilitation programme (R group, n=19)
Number of subjects: 35
Study 25268656 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin alone (C group, n=16)
Number of subjects: 35
Study 23290205 — intervention group
Group type: EXPERIMENTAL
Intervention: E-BEHAVE-AD
Number of subjects: 87
Study 23290205 — intervention group
Group type: EXPERIMENTAL
Intervention: NBRS
Number of subjects: 87
Study 23290205 — intervention group
Group type: EXPERIMENTAL
Intervention: NPI
Number of subjects: 87
Study 23290205 — intervention group
Group type: COMPARATOR
Intervention: E-BEHAVE-AD, NBRS, NPI
Number of subjects: 87
Study 21375092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron (2 ml, 4 mg)
Number of subjects: 60
Study 21375092 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 60
Study 18788503 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 0
Study 18788503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 0
Study 18788503 — intervention group
Group type: COMPARATOR
Intervention: Racemic bupivacaine
Number of subjects: 0
Study 16961773 — intervention group
Group type: EXPERIMENTAL
Intervention: Lo-Tact-1
Number of subjects: 40
Study 16961773 — intervention group
Group type: COMPARATOR
Intervention: ATG
Number of subjects: 40
Study 12767733 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25-300 mg per day)
Number of subjects: 150
Study 12767733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11039967 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial home visits by a community nurse (5 visits over 1 year)
Number of subjects: 316
Study 11039967 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 316
Study 9109860 — intervention group
Group type: COMPARATOR
Intervention: cM-T412 (anti-CD4 antibody)
Number of subjects: 29
Study 8258118 — intervention group
Group type: EXPERIMENTAL
Intervention: Perycit, 500 mg, tid, for 3 months
Number of subjects: 20
Study 8258118 — intervention group
Group type: COMPARATOR
Intervention: Trental, 100 mg, tid, for 3 months
Number of subjects: 20
Study 3996244 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic agents
Number of subjects: 34
Study 3996244 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 34
Study 30064301 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 0
Study 30064301 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy
Number of subjects: 0
Study 28796528 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 17
Study 28796528 — intervention group
Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 17
Study 26790781 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumpatellar electrocautery (denervation)
Number of subjects: 184
Study 26790781 — intervention group
Group type: COMPARATOR
Intervention: No denervation (control)
Number of subjects: 184
Study 23467055 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% urea ointment with plastic dressing
Number of subjects: 105
Study 23467055 — intervention group
Group type: COMPARATOR
Intervention: bifonazole-urea ointment
Number of subjects: 105
Study 20829341 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy (PV group, n=50): FIO2 0.5, tidal volume 6 mL/kg, positive end-expiratory pressure 5 cm H2O, pressure-controlled ventilation
Number of subjects: 100
Study 20829341 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation strategy (CV group, n=50): FIO2 1.0, tidal volume 10 mL/kg, zero end-expiratory pressure, volume-controlled ventilation
Number of subjects: 100
Study 18577309 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T)
Number of subjects: 306
Study 18577309 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1%/tobramycin 0.3% (DM/T)
Number of subjects: 306
Study 18577309 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (baseline)
Number of subjects: 306
Study 16941973 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 150
Study 16941973 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point pressing therapy
Number of subjects: 150
Study 16941973 — intervention group
Group type: COMPARATOR
Intervention: Medication (saitazan, 10 mg once daily)
Number of subjects: 150
Study 14641306 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib, 200 mg orally twice per day
Number of subjects: 200
Study 14641306 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered orally with the same dosing schedule as celecoxib
Number of subjects: 200
Study 14641306 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 200
Study 14641306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 11344213 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine infusion (4 micromol/dL.min) from 90-240 min (n=6)
Number of subjects: 18
Study 11344213 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine infusion (4 micromol/dL.min) from 0-300 min (n=6)
Number of subjects: 18
Study 11344213 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo; n=6)
Number of subjects: 18
Study 10178659 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 19394
Study 10178659 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 19394
Study 8157786 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (Timunox), 50 mg, thrice-weekly subcutaneous injections
Number of subjects: 39
Study 8157786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 2893314 — intervention group
Group type: COMPARATOR
Intervention: Low-dose intraventricular bethanechol (0.35 mg/d)
Number of subjects: 10
Study 2893314 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose intraventricular bethanechol (up to 1.75 mg/d)
Number of subjects: 10